Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs
Executive Summary
An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).
You may also be interested in...
Roche Faces Probe On Claims It Derailed Biosimilar Herceptin
Did Roche engage in abusive market conduct aimed at keeping trastuzumab biosimilar versions at bay in India? The Competition Commission of India has sought a detailed investigation into a string of serious allegations brought about by Biocon and Mylan and has held that some of the Swiss firm’s actions prima facie appear to be aimed at adversely affecting the penetration of biosimilars in the country.
Roche Faces Probe On Claims It Derailed Biosimilar Herceptin
Did Roche engage in abusive market conduct aimed at keeping trastuzumab biosimilar versions at bay in India? The Competition Commission of India has sought a detailed investigation into a string of serious allegations brought about by Biocon and Mylan and has held that some of the Swiss firm’s actions prima facie appear to be aimed at adversely affecting the penetration of biosimilars in the country.
Indian Herceptin Biosimilars Case Simmers
The hotly contested case concerning biosimilar versions of Roche's Herceptin (trastuzumab) witnessed a seesaw shift after a division bench of the Delhi High Court held that the status prevailing prior to a stinging April 25 order against Biocon Ltd. and Mylan NV will continue to operate.